Efficacy and Safety of Enteric-coated Mycophenolate Sodium in Heart Transplant Recipients
A Prospective, Open-label, Multicenter Extension Study on the Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in Heart Transplant Recipients
1 other identifier
interventional
N/A
0 countries
N/A
Brief Summary
This purpose of this extension study of patients being treated with EC-MPS is to assess the long term safety of this medication.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2003
CompletedFirst Submitted
Initial submission to the registry
October 11, 2005
CompletedFirst Posted
Study publicly available on registry
October 13, 2005
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2006
CompletedFebruary 24, 2017
February 1, 2017
3.2 years
October 11, 2005
February 22, 2017
Conditions
Keywords
Interventions
Eligibility Criteria
You may qualify if:
- Patients who were participating in the core study CERL080A2401 and have successfully completed the first 12 months of the core study
You may not qualify if:
- Patients who did not complete the 12-month core study CERL080A2401
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Officials
- STUDY DIRECTOR
Novartis
Novartis
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- PREVENTION
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 11, 2005
First Posted
October 13, 2005
Study Start
April 1, 2003
Primary Completion
June 1, 2006
Last Updated
February 24, 2017
Record last verified: 2017-02